SCHEMBL2332115

SCHEMBL2332115

CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)OCC(CCN(C)C)CO1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
ALDH1A1 P00352 4/20 0.35
F7 P08709 3/20 0.35
F3 P13726 3/20 0.35
PPARG P37231 2/20 0.35
PPARD Q03181 2/20 0.35
PPARA Q07869 2/20 0.35
DUSP3 P51452 1/20 0.35
PTPN7 P35236 1/20 0.35
KDM4E B2RXH2 1/20 0.35
FFAR1 O14842 1/20 0.35
LMNA P02545 1/20 0.35
FABP3 P05413 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP19A1 P11511 1/20 0.35
FABP4 P15090 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19882101 1.00 CNR1 (0.35) CNR1TRPV1ALDH1A1F7F3
SCHEMBL28442815 0.96 DNM1 (0.33) TRPV1ALDH1A1TSHR
SCHEMBL2328105 0.93 CNR1 (0.36) CNR1
SCHEMBL20018237 0.90 CNR1 (0.34) CNR1
SCHEMBL28477740 0.89 DNM1 (0.39) TRPV1ALDH1A1
SCHEMBL12186769 0.88 CNR1 (0.34) CNR1TRPV1DUSP3PTPN7
SCHEMBL22838309 0.87 TRPV1 (0.36) TRPV1ALDH1A1F7F3PPARG
SCHEMBL246601 0.87 TRPV1 (0.36) TRPV1ALDH1A1F7F3PPARG
SCHEMBL22838284 0.86 TRPV1 (0.36) TRPV1ALDH1A1F7F3PPARG
SCHEMBL23461836 0.85 CNR1 (0.34) CNR1TRPV1ALDH1A1F7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4495237-B1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ARBUTUS BIOPHARMA CORP (CA) 2026-05-13 EP disclosed
US-12606823-B2 Modified CPF1 guide RNA Breeze Bio, Inc. 2026-04-21 US disclosed
US-12453776-B2 Lipids and compositions for the delivery of therapeutics ARBUTUS BIOPHARMA CORPORATION (CA) 2025-10-28 US disclosed
EP-4495237-A2 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS Arbutus Biopharma Corporation (CA) 2025-01-22 EP disclosed
US-20240424105-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ARBUTUS BIOPHARMA CORPORATION (CA) 2024-12-26 US disclosed
EP-4241767-B1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ARBUTUS BIOPHARMA CORP (CA) 2024-10-23 EP disclosed
US-12042541-B2 Lipids and compositions for the delivery of therapeutics ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-23 US disclosed
EP-3757090-B1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ARBUTUS BIOPHARMA CORP (CA) 2024-06-12 EP disclosed
US-20240042039-A1 LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ARBUTUS BIOPHARMA CORPORATION (CA) 2024-02-08 US disclosed
US-11771715-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-10-03 US disclosed
US-9186325-B2 Lipids and compositions for the delivery of therapeutics TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2015-11-17 US disclosed
US-20130017223-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-01-17 US disclosed
US-20130017223-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-01-17 US disclosed
US-20110311582-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ARBUTUS BIOPHARMA CORPORATION (CA) 2011-12-22 US disclosed
US-20110311582-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ARBUTUS BIOPHARMA CORPORATION (CA) 2011-12-22 US disclosed
US-20110311582-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ARBUTUS BIOPHARMA CORPORATION (CA) 2011-12-22 US disclosed
EP-2355851-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS Alnylam Pharmaceuticals Inc. (US) 2011-08-17 EP disclosed
WO-2011075656-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-06-23 WO disclosed
WO-2010054401-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2010-05-14 WO disclosed
WO-2010054401-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12453776-B2 Lipids and compositions for the delivery of therapeutics PHOSPHO1, MBOAT1, SGMS1 CNR1 688/4885TRPV1 3211/4885ALDH1A1 2999/4885
US-11771715-B2 Circular RNA compositions and methods RTCB, HNRNPA1, HNRNPAB CNR1 4579/4885TRPV1 3359/4885ALDH1A1 4484/4885
US-20240424105-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS PHOSPHO1, MBOAT1, SGMS1 CNR1 729/4885TRPV1 3198/4885ALDH1A1 3640/4885
US-12606823-B2 Modified CPF1 guide RNA CPSF1, CPSF6, UPF1 CNR1 3590/4885TRPV1 4246/4885ALDH1A1 4235/4885
US-12042541-B2 Lipids and compositions for the delivery of therapeutics PHOSPHO1, MBOAT1, SGMS1 CNR1 688/4885TRPV1 3211/4885ALDH1A1 2999/4885
US-20130017223-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS LIPA, APOB, LIPC CNR1 3995/4885TRPV1 2780/4885ALDH1A1 4338/4885
US-20240042039-A1 LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS PHOSPHO1, MBOAT1, SGMS1 CNR1 688/4885TRPV1 3211/4885ALDH1A1 2999/4885
US-20110311582-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS APOB, LPAR3, LPAR2 CNR1 1248/4885TRPV1 4483/4885ALDH1A1 4355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.